Clinical trials: Alzheimer Disease 3
Alzheimer Type Dementia, Alzheimer's Disease (AD)
Impact of Ketoflex 12/3 Diet on Early-to-Mid Stage Alzheimer's Progression
This study investigates the effects of the Ketoflex 12/3 diet on the clinical progression of early-to-mid stage Alzheimer's disease.
- Trial name
- NCT06898424
- Testing
- Ketoflex 12/3 Diet
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Prof. Lutfu Hanoglu, MD
Agitation Associated With Dementia of the Alzheimer's Type
Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
To evaluate the superiority of brexpiprazole 1 mg or 2 mg over placebo after a 10-week treatment regimen for agitation associated with dementia of the Alzheimer's type in patients who require medication, and to investigate the…
- Trial name
- NCT03620981
- Testing
- Brexpiprazole
- Where
- Japan
- Volunteers
- 410 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Alzheimer's Disease
Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects
A Randomized, Double-blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients with Early Alzheimer's Disease
- Trial name
- NCT03817684
- Testing
- BPN14770
- Where
- 41 sites in United States
- Volunteers
- 255 people
- Sponsor
- Tetra Discovery Partners
Alzheimer's Disease
Neural Correlates In Mild Alzheimer's Disease
The objective of this study was to identify neural correlates of cognitive improvement after 3 months of donepezil hydrochloride treatment using either or both of two functional magnetic resonance imaging (fMRI) measures - the…
- Trial name
- NCT00477659
- Testing
- Donepezil hydrochloride
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Eisai Inc.
Alzheimer Disease
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.
- Trial name
- NCT06585787
- Testing
- KarXT
- Where
- 296 sites in United States, Argentina and 23 more
- Volunteers
- 406 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Alzheimer Disease
A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease
The purpose of this study is to evaluate the safety, tolerability and efficacy of GV-971 in mild to moderate Alzheimer's disease.
- Trial name
- GREEN MEMORY (NCT04520412)
- Testing
- GV-971
- Where
- 171 sites in United States, Australia and 8 more
- Volunteers
- 2,046 people
- Sponsor
- Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Alzheimer Disease, Neurofibrillary Tangle
Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD
The goal of this clinical trial is to evaluate the efficacy and safety of XTR006 injection PET visual reading in detecting brain neurofibrillary tangles (NFTs) in elderly subjects with Mild Cognitive Impairment (MCI), Alzheimer's…
- Trial name
- NCT07115238
- Testing
- XTR006
- Where
- China
- Volunteers
- 354 people, healthy volunteers welcome
- Sponsor
- Sinotau Pharmaceutical Group
Alzheimer's Disease
Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.
- Trial name
- CONCERT (NCT00829374)
- Testing
- Dimebon
- Where
- 101 sites in United States, Australia and 8 more
- Volunteers
- 1,003 people
- Sponsor
- Medivation, Inc.
Alzheimer Disease
Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects
A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects with Mild-to-Moderate Alzheimer's Disease.
- Trial name
- NCT04251182
- Testing
- 15mg T3D-959, 30 mg T3D-959, 45 mg T3D-959
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- T3D Therapeutics, Inc.
Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease
[18F]APN-1607 PET in Subjects With AD Compared to HC
The overall objective of this study is to compare the overall pattern of [18F]APN-1607 uptake in subjects with MCI, subjects with AD dementia, and healthy subjects.
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease, Healthy Volunteers
- Trial name
- NCT05542953
- Testing
- [18F]APN-1607
- Where
- China
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- APRINOIA Therapeutics
Alzheimer's Disease
DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease
The purpose of this study is to determine whether chronic DHA (Docosahexaenoic Acid) supplementation slows the progression of cognitive and functional decline in mild to moderate Alzheimer's disease (AD).
- Trial name
- DHA (NCT00440050)
- Testing
- DHA (Docosahexaenoic Acid)
- Where
- 51 sites in United States
- Volunteers
- 402 people
- Sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
Mild Cognitive Impairment, Dementia
A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment
The purpose of this study is to determine whether treatment with the investigational drug ladostigil will delay the onset of Alzheimer's disease(AD) in patients with Mild Cognitive Impairment (MCI).
- Trial name
- NCT01429623
- Testing
- ladostigil hemitartrate
- Where
- 12 sites in Austria, Germany and 1 more
- Volunteers
- 210 people
- Sponsor
- Avraham Pharmaceuticals Ltd
Alzheimer Disease
A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients
The purpose of this study is to assess the long-term safety and tolerability of bapineuzumab in subjects with Alzheimer Disease who participated in study 3133K1-3000 (NCT00667810).
- Trial name
- NCT00996918
- Testing
- Bapineuzumab 0.5 mg/kg, Bapineuzumab 1.0 m/kg
- Where
- 82 sites in Australia, Belgium and 15 more
- Volunteers
- 198 people
- Sponsor
- Pfizer
Alzheimer Disease
Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)
The purpose of this study is determine the safety, tolerability, and efficacy of 3 doses of lecozotan SR in patients with mild to moderate Alzheimer's Disease over 12 weeks.
- Trial name
- NCT00151398
- Testing
- lecozotan SR, Donepezil
- Where
- 56 sites in United States, Argentina and 3 more
- Volunteers
- 229 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer Disease
Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease
The purpose of the study is to determine the safety, tolerability, and efficacy of 3 doses of lecozotan in combination with a cholinesterase inhibitor in patients with mild to moderate Alzheimer's disease (AD).
- Trial name
- NCT00277810
- Testing
- lecozotan SR (SRA-333)
- Where
- 83 sites in United States, Argentina and 9 more
- Volunteers
- 250 people
- Sponsor
- Pfizer
Agitation in Participants With Dementia of the Alzheimer's Type
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type
Participants with agitation secondary to dementia of the Alzheimer's type. The diagnosis of probable Alzheimer's disease (AD) will be based on the "2011 Diagnostic Guidelines for Alzheimer's Disease" issued by the National…
- Trial name
- NCT02442778
- Testing
- AVP-786-18, AVP-786-28, AVP-786-42.63
- Where
- 83 sites in United States, Canada
- Volunteers
- 522 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Prurigo Nodularis
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
- Trial name
- NCT06516965
- Testing
- Povorcitinib
- Where
- 119 sites in United States, Australia and 9 more
- Volunteers
- 346 people
- Sponsor
- Incyte Corporation
Alzheimer Disease
Masitinib in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to assess the safety and efficacy of masitinib for the treatment of mild to moderate Alzheimer's Disease.
- Trial name
- NCT01872598
- Testing
- Masitinib, Standard of care
- Where
- 6 sites in Bulgaria, Greece and 4 more
- Volunteers
- 721 people
- Sponsor
- AB Science
Alzheimer's Disease
Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms
The purpose of this trial is to assess the efficacy and safety of S47445 versus placebo in patients with Alzheimer's disease at mild to moderate stages with depressive symptoms.
- Trial name
- NCT02626572
- Testing
- S47445 5mg, S47445 15mg, S47445 50mg
- Where
- 78 sites in Brazil, Bulgaria and 10 more
- Volunteers
- 500 people
- Sponsor
- Institut de Recherches Internationales Servier
Alzheimer's Disease
A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease
The purpose of this study is to assess the long-term safety and tolerability of Bapineuzumab (AAB-001, ELN115727) in subjects with Alzheimer's disease who participated in study ELN115727-301 or study ELN115727-302.
- Trial name
- NCT00937352
- Testing
- Bapineuzumab
- Where
- 191 sites in United States, Austria and 1 more
- Volunteers
- 896 people
- Sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC